Description: Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.
Home Page: www.aclaristx.com
ACRS Technical Analysis
640 Lee Road
Wayne,
PA
19087
United States
Phone:
484 324 7933
Officers
| Name | Title |
|---|---|
| Dr. Neal S. Walker D.O. | Co-Founder, CEO & Director |
| Mr. Frank Ruffo | Co-Founder, CFO & Treasurer |
| Dr. Joseph Monahan | Chief Scientific Officer |
| Dr. Douglas J. Manion Frcp(C), M.D. | Pres & COO |
| Mr. Robert A. Doody Jr. | VP of Investor Relations |
| Mr. Matthew Rothman J.D. | Gen. Counsel & Corp. Sec. |
| Dr. Jon Jacobsen Ph.D. | Sr. VP of Chemistry |
| Dr. Paul S. Changelian Ph.D. | Sr. VP of Biology |
| Mr. James Loerop | Chief Bus. Officer |
| Dr. Ian Anderson Ph.D. | Exec. VP of Translational R&D |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.9048 |
| Price-to-Sales TTM: | 43.6278 |
| IPO Date: | 2015-10-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 72 |